Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

Phase 3

Terminated

Conditions: Pancreatic Neoplasm
Neoplasm Metastasis

Interventions: Drug: 5-Fluorouracil
Drug: S-1

First Posted Date: 2008-01-28

Last Posted Date: 2016-05-26

Lead Sponsor: Sanofi

Target Recruit Count: 61

Registration Number: NCT00602745

Locations: 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

Phase 2

Completed

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: cisplatin
Drug: epirubicin hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy

First Posted Date: 2008-01-28

Last Posted Date: 2019-04-30

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT00601705

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2008-01-28

Last Posted Date: 2020-04-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 5

Registration Number: NCT00602329

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: oxaliplatin
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: conventional surgery
Procedure: endoscopic biopsy
Procedure: laparoscopy
Radiation: radiation therapy

First Posted Date: 2008-01-28

Last Posted Date: 2020-04-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 19

Registration Number: NCT00602602

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Phase 2

Terminated

Conditions: Cancer of Larynx

Interventions: Drug: Cisplatin
Drug: Cetuximab
Drug: 5-Fluorouracil
Drug: Docetaxel

First Posted Date: 2008-01-23

Last Posted Date: 2015-12-03

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT00599131

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: Proton/Photon Radiotherapy
Drug: Cisplatin
Drug: Fluorouracil

First Posted Date: 2008-01-14

Last Posted Date: 2021-10-26

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT00592501

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Phase 2

Completed

Conditions: Unresectable Adenocarcinoma of the Esophagus
Metastatic Adenocarcinoma of the Esophagus
Metastatic Adenocarcinoma of Gastric Cardia
Unresectable Adenocarcinoma of Gastric Cardia

Interventions: Drug: FOLFOX
Drug: 5-FU
Drug: Erlotinib

First Posted Date: 2008-01-11

Last Posted Date: 2021-10-01

Lead Sponsor: Translational Oncology Research International

Target Recruit Count: 38

Registration Number: NCT00591123

Locations: 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Translational Oncology Research International (TORI) Network, Los Angeles, California, United States

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Verrucous Carcinoma
Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
Recurrent Salivary Gland Carcinoma
Stage IV Major Salivary Gland Cancer AJCC v7
Stage IVA Laryngeal Verrucous Carcinoma AJCC v7
Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7
Neck Squamous Cell Carcinoma of Unknown Primary

Interventions: Drug: Cisplatin
Biological: Bevacizumab
Drug: Carboplatin
Drug: Docetaxel
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-01-09

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 403

Registration Number: NCT00588770

Locations: 🇺🇸
Cleveland Clinic-Weston, Weston, Florida, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States

and more 778 locations

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Cancer

Interventions: Radiation: IMRT
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2007-12-27

Last Posted Date: 2016-09-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 90

Registration Number: NCT00580983

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer

Not Applicable

Conditions: Nasopharyngeal Neoplasms

First Posted Date: 2007-12-19

Last Posted Date: 2013-08-22

Lead Sponsor: Hospital Authority, Hong Kong

Target Recruit Count: 798

Registration Number: NCT00577057

Locations: 🇨🇳
Tuen Mun Hospital, Hong Kong, China
🇨🇳
Prince of Wales Hospital, Hong Kong, China
🇨🇳
Pamela Youde Nethersole Eastern Hospital, Hong Kong, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy